Calcineurin activity and inhibition in skin and (epi)dermal cell cultures.
Calcineurin (Cn) is the target of the immunosuppressive drugs cyclosporine A (CsA), tacrolimus (Trl), and pimecrolimus (Prl). Trl and Prl are often used topically for treatment of various skin diseases. The Cn inhibitors CsA and Trl are mostly used for maintenance therapy of transplant patients. Their long-term use, however, causes a dramatic increase in skin cancer risk. By using a newly developed assay for Cn measurement in blood, we were able to demonstrate Cn activity in total skin homogenates. A significantly higher activity was found in epidermis compared to dermis. In skin cell cultures, fibroblasts showed the highest activity as compared to keratinocytes and melanocytes. Of the Cn inhibitors, Trl showed stronger inhibition than CsA and Prl (57 and 55% in fibroblast and keratinocyte cultures, respectively). Also, the lowest IC(50) (the half maximal inhibitory concentration) values were found for Trl (0.5 and 1.3 nM in two different fibroblast cultures). Cn activity and its inhibition can thus be studied in dermatological samples. The effects of Cn inhibition in fibroblasts and keratinocytes may be of influence on the overall functioning of the skin immune system.
Smit
N P M
NP
Department of Clinical Chemistry, Leiden University Medical Center, Leiden, The Netherlands. N.Smit@lumc.nl
Van Rossum
H H
HH
Romijn
F P
FP
Sellar
K J
KJ
Breetveld
M
M
Gibbs
S
S
Van Pelt
J
J
D019703:Calcineurin / Q000378:metabolism*; D065095:Calcineurin Inhibitors; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D004817:Epidermis / Q000201:enzymology*; D005347:Fibroblasts / Q000201:enzymology; D006801:Humans; D012867:Skin / Q000201:enzymology*; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000494:pharmacology
D065095:Calcineurin Inhibitors; C117268:pimecrolimus; D016572:Cyclosporine; D019703:Calcineurin; D016559:Tacrolimus